Initiators of biosimilar insulin glargine-yfgn were more likely to reside in rural areas, live in long-term care facilities, or have multiple prescribers and were less likely to have previously used ...
Semglee and Insulin Glargine may now be substituted for the reference product Lantus (insulin glargine) at the pharmacy counter. Viatris Inc. and Biocon Biologics have announced the launch of ...
Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its reference product, Lantus. Increases were seen across retail, mail order, and ...
The approval means that pharmacists will be allowed to switch out Lantus (insulin glargine) for the Semglee (insulin glargine-yfgn) biosimilar without the required approval from the prescribing ...
On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for the label to ...
Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog. Semglee ...
PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results